Kopecek Miloslav, Cerná Lubica, Sulak Jan, Raszka Michal, Bares Martin, Seifertová Dagmar
Prague Psychiatric Centre, Prague - Bohnice, Czech Republic.
Neuro Endocrinol Lett. 2007 Dec;28(6):889-94.
The aim of our study was to evaluate the efficacy of electroconvulsive (ECT) and venlafaxine therapy from the patient's point of view.
We used a retrospective chart review from 22 inpatients who underwent ECT and 22 patients treated with venlafaxine due to resistant unipolar or bipolar depression. We used bilateral ECT in a median of 8 (IQR 7-9.7) sessions and venlafaxine therapy with a median daily dosage of 225 mg (IQR 150-225 mg) for a median of 4 (IQR 4-5) weeks. The main outcome was change in a self-evaluation scale - Short Form of the Beck Depression Inventory (BDI-SF). The response was defined as the decreasing of the BDI-SF score by >or=50%, remission as decreasing of BDI-SF score <or=4.
We did not find significant differences between sex, age and BDI-SF before therapy in both groups. The reduction of BDI-SF score was significantly higher in the ECT group than in venlafaxine group (p=0.025). Significantly more patients treated with ECT reached response than patients treated with venlafaxine (68% vs. 23%; <0.01). The remission rate after ECT was not significantly higher than venlafaxine therapy (27% vs. 5%; p=0.094). The number needed to treat (NNT) of ECT for BDI-SF response was 3 (CI95% 1.4 to 5.2) and NNT for BDI-SF remission was 5 (CI95% 2.3 to 45.8).
After the median of 3 failed antidepressant trials, ECT was more effective than venlafaxine in the short term therapy in some parametres according to our patients. We suggest that the fact that mental state was evaluated by patients themselves is an important pro-argument in the discussion about ECT.
我们研究的目的是从患者的角度评估电休克治疗(ECT)和文拉法辛治疗的疗效。
我们对22例接受ECT治疗的住院患者和22例因难治性单相或双相抑郁症接受文拉法辛治疗的患者进行了回顾性病历审查。我们采用双侧ECT,中位疗程为8次(四分位间距7 - 9.7次),文拉法辛治疗的中位日剂量为225毫克(四分位间距150 - 225毫克),中位疗程为4周(四分位间距4 - 5周)。主要结局是自我评估量表——贝克抑郁量表简版(BDI - SF)的变化。缓解定义为BDI - SF评分降低≥50%,痊愈定义为BDI - SF评分降低≤4分。
两组在治疗前的性别、年龄和BDI - SF方面未发现显著差异。ECT组BDI - SF评分的降低显著高于文拉法辛组(p = 0.025)。接受ECT治疗达到缓解的患者显著多于接受文拉法辛治疗的患者(68%对23%;p<0.01)。ECT后的痊愈率并不显著高于文拉法辛治疗(27%对5%;p = 0.094)。ECT使BDI - SF缓解所需治疗人数(NNT)为3(95%可信区间1.4至5.2),使BDI - SF痊愈所需治疗人数为5(95%可信区间2.3至45.8)。
在中位3次抗抑郁试验失败后,根据我们的患者情况,在某些参数方面,ECT在短期治疗中比文拉法辛更有效。我们认为,患者自身对精神状态进行评估这一事实在关于ECT的讨论中是一个重要的支持论据。